AstraZeneca Iressa Link To Interstitial Lung Disease Questioned In Review

Iressa’s link to interstitial lung disease is uncertain given the similar rate of ILD seen in patients receiving the AstraZeneca drug and placebo, FDA Office of Drug Evaluation I Director Robert Temple, MD, states in a "Feb. 19 review memo.